Hormones in breast cancer: update 1978

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Cytoplasmic estrogen receptor (ER) assays are established for advanced breast cancer treatment strategies.
• The predictive value of ER assays in primary tumors for early recurrence and survival is a novel finding.
• The role of nuclear-bound ER requires further elucidation.

Purpose of the Study:

• To explore the utility of ER assays in primary breast tumors for predicting patient outcomes.
• To validate progesterone receptor measurements as a marker for hormone dependence in advanced breast cancer.
• To identify safe and effective endocrine therapies for adjuvant breast cancer treatment.

Main Methods:

• Analysis of estrogen receptor (ER) assays in primary breast tumor specimens.
• Evaluation of progesterone receptor measurements as a biomarker.
• Assessment of antiestrogen therapies for breast cancer.

Main Results:

• ER assays in primary tumors show potential for predicting early recurrence and survival.
• Progesterone receptor measurements are gaining support as a marker for hormone dependence.
• Antiestrogens demonstrate promise as safe and effective endocrine therapies with good patient compliance.

Conclusions:

• ER assays in primary breast tumors may soon be integrated into adjuvant therapy trials.
• Progesterone receptor assays may become routine in therapeutic decision-making for advanced breast cancer.
• The development of endocrine therapies based on biological principles marks a shift from empirical approaches in breast cancer treatment.